Sesen Bio (SESN) Tops Q1 EPS by 40c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. AXP
6. T
7. TMUS
8. UNH
9. BRO
10. SPY

Go back to Sesen Bio (SESN) Tops Q1 EPS by 40c

Sesen Bio (SESN) Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium

May 7, 2020 5:27 PM EDT

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that the Company has received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the regulatory pathway for Vicinium in Europe. The Companys lead program, Vicinium, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company... More